Anti-InflammatoryTier 2 β Good human studies
Larazotide
AT-1001 Β· Larazotide Acetate
Tight junction regulatory peptide that reduces intestinal permeability. Clinically studied in coeliac disease with demonstrated reduction of intestinal leakiness.
π Oralπ§ Room temperature; follow compounding pharmacy instructions
Want a personalised protocol?
Our AI generator builds a protocol tailored to your profile and goals.
Mechanism of Action
Octa-peptide that competes with zonulin receptor binding, preventing tight junction opening. Directly reduces intestinal permeability without immunosuppression.
Clinical Applications
- βCoeliac disease (phase 3 clinical studies)
- βLeaky gut syndrome
- βFood sensitivities related to intestinal permeability
- βIBD management
- βSIBO and dysbiosis
Dosing Protocol
Recommended Dosing
Oral. 0.5β1 mg three times daily, with meals. Cycles of 8β12 weeks. Well tolerated in phase 2/3 trials up to 24 weeks.Safety & Contraindications
Possible Side Effects
- β Headache (most reported in trials)
- β Nausea
- β Diarrhoea (paradoxical, transient)
- β Generally very well tolerated
Contraindications
- βPregnancy
- βKnown hypersensitivity
Combinations & Synergies
π BPC-157synergistic gut repair and permeability control
π KPVtight junction repair plus mucosal anti-inflammation